Rural Care Investment: Kansas’ HaysMed highlighted plans for a new PET/CT scanner funded by $2.4M in Rural Health Transformation Program support, aiming to bring advanced oncology and cardiac diagnostics closer to western Kansas. Maternal Health Access: Cape Fear Valley Health received a $1.6M Duke Endowment grant to join the MIH Carolinas initiative, expanding early pregnancy and postpartum screening and referrals for mental health and social needs. Cord Blood Banking Expansion: Sidra Medicine partnered with The View Hospital in Qatar to offer umbilical cord blood banking to eligible expectant families, with samples processed and stored under GMP standards. AI in Healthcare Rules: Kuwait’s Ministry of Health issued a practical guide for regulating AI language tools and large language models, stressing patient privacy and that AI outputs can’t replace clinical judgment. Medicaid Coverage Shift for Trans Youth: The Trump administration said Medicaid will stop paying for gender-affirming surgeries and hormone treatments for transgender minors, with CHIP also affected for under-19s. Public Health Alerts: Wisconsin confirmed two measles cases in southern counties, urging monitoring and possible exposure follow-up. Clinical Trial Progress: Health Canada authorized Moderna to start a Phase I trial for a Bundibugyo Ebola mRNA vaccine candidate. Healthcare Tech & Services: Kyndryl agreed to acquire Healthcare IT Leaders to expand EHR, cloud, data analytics, and AI-led modernization consulting for providers and payors. Oncology Milestone: St. Joseph’s Medical Center in Stockton completed its 1,000th Y90 radioembolization procedure for liver cancer. Drug Safety/Compliance: Health officials reported swine flu detected among pigs at Michigan’s Kent County Youth Fair, advising close contacts to watch for flu-like symptoms. Policy & Coverage Pressure: Nebraska advanced LB912 and LB958, updating Medicaid waiver rules and health worker training/compact requirements. Pharma/Market Watch: Multiple investor alerts flagged potential securities issues at ARS Pharmaceuticals and Regeneron, alongside broader pharma communication and trial coverage discussions.